While US FDA Commissioner Scott Gottlieb touted the 21st Century Cures Act's inclusion of the limited population antibacterial drug (LPAD) pathway as a way to spur antibiotics to market, he stressed the need for pull incentives focusing on the reimbursement of limited use anti-infectives.
The agency is working on one such step with the Centers for Medicare and Medicaid Services (CMS), Gottlieb explained at...







